Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS)
Shanghai, CN
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.69% | +4.19% | -11.96% | +8.52% | -1.92% | +8.18% | +11.10% | +249.65% | +201.54% | +19.11% | +19.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+251.8% ★ Q1'26: +38.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+317.5% ★ Q1'26: +70.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+74.3% ★ Q1'26: +31.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+78.2% ★ Q1'26: +44.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+41.1% ★ Q1'26: +9.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: +1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 4 EPS Ana. |
Dec 2027 1 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
655.01M
est: 865.05M (-24.3%)
|
928.81M
est: 1.15B (-19.0%)
|
825.49M
est: 969.62M (-14.9%)
|
1.01B
est: 995.90M (+1.8%)
|
1.19B
est: 1.20B (-0.2%)
|
4.20B
est: 4.08B (+2.9%)
|
1.67B
1.67B – 1.67B
-59.1% YoY
|
1.85B
1.85B – 1.85B
+10.5% YoY
|
2.06B
2.06B – 2.06B
+11.5% YoY
|
| EBITDA |
-146.26M
est: 88.27M (-265.7%)
|
82.24M
est: 117.03M (-29.7%)
|
152.68M
est: 98.94M (+54.3%)
|
408.31M
est: 101.62M (+301.8%)
|
836.34M
est: 523.75M (+59.7%)
|
3.41B
est: 1.79B (+91.1%)
|
731.32M
731.32M – 731.32M
-59.1% YoY
|
808.40M
808.40M – 808.40M
+10.5% YoY
|
901.68M
901.68M – 901.68M
+11.5% YoY
|
| EBIT |
-282.28M
est: -33.43M (-744.5%)
|
-53.22M
est: -44.32M (-20.1%)
|
30.27M
est: -37.47M (+180.8%)
|
312.23M
est: -38.48M (+911.4%)
|
708.83M
est: 397.91M (+78.1%)
|
3.29B
est: 1.36B (+142.1%)
|
555.61M
555.61M – 555.61M
-59.1% YoY
|
614.17M
614.17M – 614.17M
+10.5% YoY
|
685.04M
685.04M – 685.04M
+11.5% YoY
|
| Net Income |
-217.46M
est: -37.01M (-487.6%)
|
18.06M
est: 37.01M (-51.2%)
|
49.30M
est: 12.34M (+299.6%)
|
294.61M
est: 238.49M (+23.5%)
|
704.58M
est: 534.30M (+31.9%)
|
2.94B
est: 2.96B (-0.9%)
|
494.06M
388.49M – 599.63M
-83.3% YoY
|
580.33M
580.33M – 580.33M
+17.5% YoY
|
814.94M
814.94M – 814.94M
+40.4% YoY
|
| SGA |
470.43M
est: 362.09M (+29.9%)
|
367.15M
est: 480.10M (-23.5%)
|
333.18M
est: 405.86M (-17.9%)
|
314.89M
est: 416.86M (-24.5%)
|
316.55M
est: 328.82M (-3.7%)
|
—
est: 1.12B (-100.0%)
|
459.13M
459.13M – 459.13M
-59.1% YoY
|
507.52M
507.52M – 507.52M
+10.5% YoY
|
566.08M
566.08M – 566.08M
+11.5% YoY
|
| EPS |
-0.37
est: -0.06 (-516.7%)
|
0.03
est: 0.06 (-50.0%)
|
0.08
est: 0.02 (+300.0%)
|
0.48
est: 0.39 (+24.1%)
|
1.14
est: 1.16 (-1.7%)
|
4.76
est: 4.75 (+0.2%)
|
0.79
0.63 – 0.97
-83.4% YoY
|
0.94
0.94 – 0.94
+19.0% YoY
|
1.32
1.32 – 1.32
+40.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hongmei Niu | Chief Financial Officer | — | female |
| Lirong Zheng | Accounting Supervisor | — | — |
| Qi Zhang | Secretary of Board of Directors | — | male |
| Yanli Liu | GM & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688336.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
